Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$127.29 USD
+1.10 (0.87%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $127.29 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABT 127.29 +1.10(0.87%)
Will ABT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABT
HCA Beats Q2 Earnings on Higher Admissions, Ups '25 EPS View
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
ABT: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Wells Fargo, Abbott Laboratories, American Express, TSS and Maui Land & Pineapple
Top Stock Reports for Wells Fargo, Abbott & American Express
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Other News for ABT
IXJ: A Bet On Global Healthcare Recovery
This New ETF Brings Out The Best In S&P 500 Without The Tech Overload
Thermo Fisher Scientific Inc Sees Significant Reduction in Eaton Vance Worldwide Health ...
BME: The Resilient Income Investment Of The Healthcare Industry
Best Dividend Aristocrats For August 2025